Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
NCT07135427
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alpha 1-Antitrypsin
- COPD
- Antibody Deficiency
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Alabama at Birmingham
- Last updated on ClinicalTrials.gov
- November 10, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.